Novavax, Inc. (NASDAQ:NVAX) shares traded -2.28% lower at $4.72 on Wall Street last session.
NVAX stock price is now 3.01% away from the 50-day moving average and -26.59% away from the 200-day moving average. The market capitalization of the company currently stands at $660.56M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $15, B. Riley Securities recently Upgraded its rating from Neutral to Buy for Novavax, Inc. (NASDAQ: NVAX). On April 20, 2023, TD Cowen Downgraded its previous ‘Outperform’ rating to ‘Market Perform’ on the stock reducing its target price from $55 to quote $10, while ‘B. Riley Securities’ rates the stock as ‘Neutral’
A total of 5.82% of the company’s stock is owned by insiders.
During the past 12 months, Novavax, Inc. has had a low of $3.53 and a high of $11.36. The fifty day moving average price for NVAX is $4.5804 and a two-hundred day moving average price translates $6.4143 for the stock.
The latest earnings results from Novavax, Inc. (NASDAQ: NVAX) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$1.44, missing analysts’ expectations of -$0.45 by -0.99. This compares to -$2.25 EPS in the same period last year. The company reported revenue of $291.34 million for the quarter, compared to $357.4 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -18.48 percent. For the current quarter, analysts expect NVAX to generate $101.45M in revenue.
Novavax, Inc.(NVAX) Company Profile
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
